Jubilant Pharmova Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 18 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹14.7K Cr
Specialty Chemicals and Nutrition segments expected to sustain growth; Specialty to contribute 65%-70% of overall EBITDA going forward. Specialty Chemicals and Nutrition segments expected to sustain strong growth, contributing ~63% revenue and 90% EBITDA. - Specialty segment EBITDA expected to remain at 65%-70% of overall company EBITDA in steady state. - Anticipated recovery and volume growth in Acetyls segment, with margins expected to improve. - Double-digit volume growth anticipated in specialty portfolio and export markets including the US, Europe, and Japan. - Lean 2.0 cost optimization program targeting Rs.
From Jubilant Pharmova Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹880
Market Cap
₹14.7K Cr
P/E Ratio
33.8
How does Jubilant Pharmova Ltd rank in Pharmaceuticals & Biotechnology?
Compare Jubilant Pharmova Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Jubilant Pharmova Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.3K Cr, net profit ₹119 Cr.
Full financials →📊 Revenue & Sales Performance
- →Specialty Chemicals and Nutrition segments expected to sustain growth; Specialty to contribute 65%-70% of overall EBITDA going forward.
- →Overall business is projected to grow at 20%-25% year-on-year driven by specialty and export growth.
- →CDMO business pipeline is strong, with 70+ active opportunities; pharma funnel has doubled in one year.
- →Agro CDMO contracts progressing; more contracts expected in coming months.
- →Semiconductor segment has 12+ opportunities, with near commercial stage molecules.
- →New multipurpose plants and capacity debottlenecking underway to support growth.
- →Niacinamide plant commissioning to accelerate growth in human nutrition.
- →Big agro CDMO order supplies to start early 2026.
- →Recovery expected in Acetyl segment with improving volumes and margins.
- →US and Rest of World revenues growing strongly (US +11% YoY, ROW +45% YoY).
- →CAPEX of ~Rs.600 crore planned in FY’26 focusing on capacity expansions.
📈 Profitability & Margins
- →Specialty Chemicals and Nutrition segments expected to sustain strong growth, contributing ~63% revenue and 90% EBITDA.
- →Specialty segment EBITDA expected to remain at 65%-70% of overall company EBITDA in steady state.
- →Anticipated recovery and volume growth in Acetyls segment, with margins expected to improve.
- →Double-digit volume growth anticipated in specialty portfolio and export markets including the US, Europe, and Japan.
- →Lean 2.0 cost optimization program targeting Rs. 100+ crore annualized savings in FY’26.
- →CDMO business pipeline expanding significantly, with large upcoming contracts expected to drive growth starting early 2026.
- →Niacinamide and human nutrition segments poised for accelerated growth due to new plant ramp-up.
- →Overall company EBITDA rose 29% YoY in Q1 FY’26; profit after tax increased 54% YoY.
- →Capex of Rs. 600 crore planned in FY’26 to support these growth initiatives.
- →Expect to reach near 70%-80% capacity utilization of Rs. 2,000 crore CAPEX by FY’27, supporting revenue ~Rs. 6,500 crore.
🏗️ Capital Expenditure Plans
- →Completed Rs. 2000 crore investment largely into specialty chemicals, including multipurpose and dedicated plants for CDMO and Fine Chemicals.
- →Major dedicated plant construction in Bharuch expected to complete by end of FY'26.
- →Commissioning of a new boiler at Bharuch scheduled for Q2 FY'26.
- →Debottlenecking initiatives to increase capacity by 15%-20% at existing multipurpose plants in Bharuch and Gajraula.
- →Detailed engineering started for a new multipurpose plant (MPP8) at Gajraula, with construction expected to begin in the next few months.
- →Conversion of recently commissioned niacinamide plant into a multipurpose plant for human nutrition segment underway.
- →Overall CAPEX planned at Rs. 600 crore for FY’26, primarily funded through internal accruals.
- →Ongoing strategic investments to support growth in CDMO, Agro, Semiconductor segments, and specialty chemicals, including R&D enhancements.
💰 Fundraising & Capital Structure
- →There is no explicit mention of any new fundraising through debt or equity in the provided transcript.
- →The company indicated that the capital expenditure (CAPEX) incurred during the quarter (~Rs. 54 crore) was primarily funded through internal accruals.
- →The net debt as of 30th June was Rs. 700 crore, with a stable net debt to EBITDA ratio of 1.18x.
- →For FY’26, the planned CAPEX is Rs. 600 crore, but no mention of raising external funds was made.
- →Overall, the company appears to be funding growth and CAPEX through internal resources rather than through fresh debt or equity as per the current disclosures.
📋 Order Book & Pipeline
- →The CDMO business pipeline has doubled in the last year, with about 70 molecules in the funnel, representing addressable markets running into thousands of crores.
- →Orders include a big $300 million agro CDMO contract, with plant construction ongoing and supplies expected to start early 2026.
- →Two agro CDMO contracts were awarded last year; five to six more are in advanced stages or discussions.
- →Multiple opportunities exist in pharma, agro, and semiconductor segments, with 12+ pipeline opportunities in semiconductor alone.
- →The company is actively engaging with 30+ key accounts across geographies (EU, US, Japan) to convert opportunities into orders.
- →Debottlenecking and capacity expansions are in progress to meet the expected demand from these orders.
- →Management is confident about converting 70%-80% of pipeline opportunities over time but notes that external factors can influence timelines.
Key Metrics
Frequently Asked Questions
What were Jubilant Pharmova Ltd Q1 FY26 results?
Specialty Chemicals and Nutrition segments expected to sustain growth; Specialty to contribute 65%-70% of overall EBITDA going forward. Specialty Chemicals and Nutrition segments expected to sustain strong growth, contributing ~63% revenue and 90% EBITDA. - Specialty segment EBITDA expected to remain at 65%-70% of overall company EBITDA in steady state. - Anticipated recovery and volume growth in Acetyls segment, with margins expected to improve. - Double-digit volume growth anticipated in specialty portfolio and export markets including the US, Europe, and Japan. - Lean 2.0 cost optimization program targeting Rs.
What is Jubilant Pharmova Ltd share price analysis?
Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 33.8 with a market cap of ₹14,730 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Pharmova Ltd planning capital expenditure?
Completed Rs.
Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.